Niagen Bioscience, Inc.
NAGE Healthcare Biotechnology
Niagen Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $129.4 million, up 29.9% from fiscal 2024. In the quarter to June 2026, revenue fell 4.28%, EPS fell 80.0% and free cash flow grew 140.6%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow NAGE
Niagen Bioscience, Inc. (NAGE) P/E ratio
As of 16 October 2026, Niagen Bioscience, Inc. (NAGE) trades at a P/E ratio of 12.5×. Over the past ten years it has ranged from 0.0× (September 2024) to 518× (November 2024); the current reading is higher than 83% of that period. That is above the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 27.7× | (46.21%) |
| FY2024 | 51.4× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 16.0× | (13.20%) |
| Mar 2026 | 18.4× | (33.55%) |
| Dec 2025 | 27.7× | (19.98%) |
| Sep 2025 | 34.6× | (44.85%) |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| LYEL Lyell Immunopharma, Inc. compare | n/m |
| IFRX InflaRx N.V. compare | n/m |
| ZNTL Zentalis Pharmaceuticals, Inc. compare | n/m |
| RNAC Cartesian Therapeutics, Inc. compare | n/m |
| IVVD Invivyd, Inc. compare | n/m |
| LRMR Larimar Therapeutics, Inc. compare | n/m |
| PRQR ProQR Therapeutics N.V. compare | n/m |
| CGEN Compugen Ltd. compare | 5.2× |
| NAGE Niagen Bioscience, Inc. | 12.5× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)